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Background: We sought to evaluate impact of extended-release niacin (ER-niacin) vs. placebo on: a) endothelial function, as assessed 
by natural logarithmic scaled reactive hyperemia index (L_RHI); and b) Endothelial Progenitor Cell (EPC) mobilization, as assessed by 
Colony Forming Units (EPC-CFU)/ml of peripheral blood; measured at baseline, one month, and 12 months in patients with intermediate 
saphenous vein graft (SVG) lesions.
methods:  Patients with intermediate (30-60% diameter stenosis) SVG lesions were entered into one-month open-label run-in dosing of 
ER-Niacin and then randomized to ER-niacin vs. placebo for 11 months. Enrollment was stopped early after the Heart Protection Study 2 - 
Treatment of HDL to Reduce the Incidence of Vascular Events trial results. Blinded assessment of Reactive Hyperemia Peripheral Arterial 
Tonometry using the EndoPAT 2000 device and EPC using flow cytometry were performed at enrollment, one and 12 months.
results:  Thirty-eight patients were randomized to ER-niacin (n=19) or placebo (n=19). Baseline clinical characteristics, and L_RHI at one 
and 12 months were similar between both groups, whereas EPC-CFU/ml of peripheral blood tended to increase in the niacin group and 
decrease in the placebo group (Table).
Conclusion:  Among patients with intermediate SVG lesions, administration of ER-niacin tended to increase EPC mobilization but did not 
affect endothelial function; however, the study was underpowered due to early termination of enrollment.
Niacin (n=19) Placebo (n=19) p
Baseline L_RHI 0.26 ±0.1 0.27±0.1 0.89
1 month L_RHI 0.26 ±0.1 0.29±0.2 0.57
12 month L_RHI 0.24 ±0.2 0.26.±0.2 0.76
LogDifference in L_RHI between baseline and 12 months -0.038±0.1 -0.002±0.1 0.52
LogDifference in L_RHI between 1 month and 12 months 0.003±0.1 -0.058±0.1 0.39
Baseline EPC-CFU/ml 23.3±20.4 43.5±93.6 0.39
1 month EPC-CFU/ml 18.7±16.7 30.4±22.3 0.09
12 month EPC-CFU/ml 27.4±26.8 15.2±20.8 0.15
Change in EPC-CFU/ml between baseline and 12 months 4.1±39.5 -30.6±102.6 0.20
Change in EPC-CFU/ml between 1 month and 12 months 8.6±28.4 -15.9±30.2 0.022
